Trump Strikes Drug Pricing Deal With Pfizer, Launches TrumpRx

During an Oval Office event alongside top health officials and Pfizer Chief Executive Albert Bourla, Trump said the program will initially include popular treatments such as Eucrisa for dermatitis, Xeljanz for rheumatoid arthritis, and Zavzpret for migraines. The White House added that patients would be able to pay cash for these medications directly through the site, which will be operated by the federal government.

Pfizer confirmed it would participate in TrumpRx, pledging to provide many of its primary care and select specialty medicines at deep discounts—some as high as 85% off list prices. On average, savings are expected to hover around 50%, per the Wall Street Journal. Trump claimed certain drugs could be available at discounts ranging from 50% to 100%.

In a separate deal, Pfizer said it will extend “most favored nation” pricing to Medicaid for all of its drugs, meaning the program will receive the lowest prices available to any U.S. payer. The company also promised to introduce new medicines at these reduced rates. In exchange, the drugmaker will receive a three-year exemption from national-security-related tariffs, provided it boosts domestic manufacturing investments.

Related: Trump Targets Big Pharma With Tough New Drug Pricing Rules

Shares in Pfizer rose 6.2% following the announcement. Analysts noted that the company has also pledged $70 billion in U.S.-based research and manufacturing, a move that may strengthen ties with the administration even if much of the spending had already been planned.

The Trump administration is also negotiating with other major pharmaceutical companies, with Eli Lilly among those mentioned. Officials said similar agreements could be unveiled soon. Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services, remarked, “We have much more to come.”

The deal represents the culmination of Trump’s earlier warnings to the industry. Last week, he threatened 100% tariffs on brand-name drugs if manufacturers failed to produce in the U.S. Bourla acknowledged that those threats played a role in reaching the agreement.

Health Secretary Robert F. Kennedy Jr. credited Trump’s personal involvement in securing Pfizer’s cooperation, saying the president’s calls and negotiations helped finalize the arrangement. A White House spokesman added that Trump is achieving what both parties have sought for decades—real reductions in drug prices for American patients.

Source: The Wall Street Journal